A Clinical Trial About the Safety of Surgical Treatment in Severe Primary Pontine Hemorrhage
Not Applicable
Recruiting
- Conditions
- Cerebrovascular DisordersPontine HemorrhagePrimarySurgery
- Interventions
- Other: life supportProcedure: hematoma evacuation by craniotomyProcedure: hematoma evacuation by stereotactic punctureProcedure: hematoma evacuation by neuroendoscopy
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT04647162
- Locations
- π¨π³
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
π¨π³Xuhui Hospital of Zhongshan Hospital affiliated to Fudan, Shanghai, China
π¨π³The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Evaluation of Short-term Outcomes of Day Surgery for Patients With CuRC
- Conditions
- Colorectal Cancer
- Interventions
- Other: Day surgery
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04646915
- Locations
- π¨π³
Guoxue Road 37#,West China Hospital, Chengdu, Sichuan, China
Prediction Model for Lateral Lymph Node Metastasis
- Conditions
- Rectal Cancer
- Interventions
- Procedure: lateral lymph node dissection
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04635488
- Locations
- π¨π³
Guoxue Road 37#,West China Hospital, Chengdu, Sichuan, China
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Phase 1
Recruiting
- Conditions
- Anti-PD-1 AntibodyRadiotherapyRectal CancerMSI-HMmr Deficiency
- Interventions
- Radiation: Hypofractionated Radiotherapy
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04636008
- Locations
- π¨π³
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1
Phase 4
- Conditions
- HepatitisPrimary Biliary CholangitisAutoimmune
- Interventions
- Drug: Ursodeoxycholic acid onlyDrug: Ursodeoxycholic acid combined with total glucosides of paeony
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 137
- Registration Number
- NCT04618575
- Locations
- π¨π³
West China Hospital, Chengdu, Sichuan, China
Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II
Phase 4
- Conditions
- Hepatitis, AutoimmunePrimary Biliary Cholangitis
- Interventions
- Drug: Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04617561
- Locations
- π¨π³
Division of Gastroenterology & Hepatology,West China Hospital,Sichuan University, Chengdu, Sichuan, China
Pregnancy Registry in West China
- Conditions
- Pregnant Women
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 53667
- Registration Number
- NCT04607499
Outcomes of Transrenal Artery Perfusion Versus Transrenal Vein Perfusion Using LifePort for Deceased Donor Kidney Transplantation
Not Applicable
Completed
- Conditions
- Organ PreservationKidney Transplantation
- Interventions
- Device: LifePort transrenal vein perfusionDevice: LifePort transrenal artery perfusion
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT04569682
- Locations
- π¨π³
West China Hospital, Sichuan University, Chengdu, China
Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
Recruiting
- Conditions
- HBVKidney Transplantation
- Interventions
- Other: prophylaxis regimen
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04562051
- Locations
- π¨π³
Tao Lin, Chengdu, Sichuan, China
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
Phase 2
- Conditions
- ImmunotherapyStage IV HCCSBRT
- Interventions
- Drug: Anti-PD-1 antibody drug named SintilimabRadiation: Stereotactic body radiation therapy
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT04547452
- Locations
- π¨π³
West China Hospital, Chengdu, Sichuan, China
Β© Copyright 2025. All Rights Reserved by MedPath